The TOPICAL trial

Share :
Published: 3 Aug 2010
Views: 8660
Dr Siow Ming Lee, University College London, UK
Dr Lee speaks about the TOPICAL trial, a randomised phase III trial of erlotinib in chemotherapy-naive patients with advanced non-small cell lung cancer who are unsuitable for first-line chemotherapy. Erlotinib was shown to significantly increase progression free survival in female patients but not in males.